Statin reduces triglyceride level via activating PPARα and upregulating apolipoprotein A5 in hypertriglyceridemic rats
10.3760/cma.j.issn.0253-3758.2010.11.017
- VernacularTitle:他汀类药物通过激活PPARα和升高大鼠载脂蛋白A5降低甘油三酯
- Author:
Xiansheng HUANG
;
Shuiping ZHAO
;
Lin BAI
;
Qian ZHANG
;
Min HU
;
Wang ZHAO
- Publication Type:Journal Article
- Keywords:
Apolipoproteins A;
Triglycerides;
PPARα;
Statins
- From:
Chinese Journal of Endocrinology and Metabolism
2010;26(11):981-985
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the potential role of apolipoprotein A5 (ApoA5) on the hypertriglyceridemia (HTG)-lowering effects of statin. Methods Twenty-four Sprague-Dawley rats were assigned to 3 groups:(1)control group, with no special treatment. (2) HTG group, treated with 10% fructose water for 6 weeks. (3) statin 4 weeks. Body weight, fasting plasma lipids, and the hepatic expressions of ApoA5 and PPARα were determined. In separate in vitro experiments, the effects of atorvastatin on triglyceride (TG) and the expressions of ApoA5 and PPARα in HepG2 cells were tested. Results (1) Plasma TG was higher in HTG group than in controls group, which was significantly reduced in statin group (both P ＜ 0. 05). (2) Rat hepatic ApoA5expression in HTG group was significantly lower than in control group and it was significantly higher in statin group than in HTG group (both P＜0. 05). (3) Similarly, rat PPARα mRNA expression in HTG group was lower than in control group and it was higher in statin group than in HTG group (both P ＜ 0.05). (4) Statin significantly upregulated the expressions of ApoA5 and PPARα and decreased TG in HepG2 cells, which was blocked in the presence of PPARα inhibitor. Conclusion Upregulation of ApoA5 expression contributes to TG lowering effect of statin via PPARα signaling pathway.
